Recruiting PHASE3 INTERVENTIONAL 4-arm NCT07218809

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01)

A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Sponsor: AstraZeneca

Conditions Epithelial Ovarian Cancer

Interventions AZD5335 Mirvetuximab Soravtansine (MIRV) Paclitaxel Pegylated liposomal Doxorubicin (PLD) Topotecan

Updated 2 times since 2025 Last updated: Jan 15, 2026 Started: Dec 29, 2025 Primary completion: Nov 17, 2028 Completion: May 27, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07218809, this PHASE3 trial focuses on Epithelial Ovarian Cancer and remains actively recruiting participants. Sponsored by AstraZeneca, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
European Network of Gynecological Oncological Trial Groups (ENGOT)
GOG Foundation, Inc. (GOG Foundation)
Ventana Medical Systems, Inc

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aarhus, Denmark , Adelaide, Australia , Amiens, France , Athens, Greece , Auchenflower, Australia , Avignon, France , Beijing, China , Bengbu, China , Bhubaneswar, India and 94 more locations